Less Ads, More Data, More Tools Register for FREE

Pin to quick picksCOS.L Regulatory News (COS)

  • There is currently no data for COS

Half Yearly Report

10 Dec 2013 07:00

RNS Number : 1046V
Healthcare Investment Opportunities
10 December 2013
 



Healthcare Investment Opportunities plc

 

Unaudited Statement of Comprehensive Income

for the six months to 30 September 2013

 

Healthcare Investment Opportunities plc (AIM: HIO), an investment company focusing on the healthcare sector, is pleased to announce its inaugural set of unaudited interim results for the six month period ended 30 September 2013. These have been posted to shareholders today and are available on the Company's website at www.healthcareinvestmentopps.co.uk.

 

Commenting on the results, David Evans, Chairman of Healthcare Investment Opportunities plc said:

 

"Since HIO listed on AIM in April 2013, both the board and myself have been actively reviewing acquisition opportunities, and have looked at over 30 opportunities in this time. We are delighted that the proposed acquisition of Collbio Limited was announced earlier this morning and are confident that the acquisition will be value enhancing for shareholders if the transaction is approved at the general meeting scheduled for 27 December 2013."

 

Enquiries:

 

Healthcare Investment Opportunities Plc

David Evans, Chairman

 

Tel: 07740 084 452

Zeus Capital (Nominated Adviser and Broker)

Corporate Finance

Ross Andrews

John Depasquale

Tel: 0161 831 1512

 

Institutional Sales

John Goold

Dominic Wilson

 

 

Tel: 020 7533 7727

Tel: 020 7533 7721

Walbrook PR Ltd

Tel: 020 7933 8780 or hio@walbrookpr.com

Paul McManus 

Mike Wort

Mob: 07980 541 893

 

 

 

Unaudited Statement of Comprehensive Income

6 months to 30 September 2013

£

Continuing operations

Administrative expenses

(62,631)

OPERATING LOSS

(62,631)

Interest receivable and similar income

-

LOSS BEFORE TAXATION

(62,631)

Tax on loss on ordinary activities

-

LOSS FOR THE PERIOD

(62,631)

 

Other comprehensive income, net of tax

-

TOTAL COMPREHENSIVE LOSS FOR THE PERIOD ATTRIBUTABLE TO OWNERS OF THE PARENT

(62,631)

 

LOSS PER ORDINARY SHARE (PENCE)

Basic

(Note 2)

(0.15)p

Diluted

(Note 2)

(0.15)p

 

 

Unaudited Statement of Changes in Equity

 for the six month period to 30th September, 2013

 

 

Share

Share

premium

Retained

Total

capital

account

earnings

Equity

£

£

£

£

(Loss) for the six month period

-

-

(62,631)

(62,631)

Funds raised

405,000

3,645,000

-

4,050,000

Issue expenses

-

(360,060)

-

(360,060)

At 30th September, 2013

405,000

3,284,940

(62,631)

3,627,309

 

 

Unaudited Statement of Financial Position

as at 30th September 2013

 

 

£

As at 30 September 2013

ASSETS

Current assets

Cash and cash equivalents

3,632,309

3,632,309

TOTAL ASSETS

3,632,309

LIABILITIES

Current liabilities

Trade and other payables

5,000

NET CURRENT ASSETS

3,627,309

NET ASSETS

3,627,309

TOTAL EQUITY

Called up share capital

405,000

Share premium account

3,284,940

Retained earnings

(62,631)

3,627,309

 

 

 

Unaudited Cash Flow Statement

for the six month period to

30th September 2013

 

 

6 months

30 September 2013

£

Cash flows from operating activities

Operating (loss) for the period

(62,631)

Increase in trade and other payables

5,000

Cash generated from operations

(57,631)

Income taxes received

-

Net cash used in operating activities

(57,631)

Cash flows from financing activities

Proceeds from issue of share capital

4,050,000

Expenses of share issue

(360,060)

Net cash generated from financing activities

3,689,940

Net increase in cash and cash equivalents

3,632,309

Cash and cash equivalents at end of the period

3,632,309

 

 

 

 

Notes to the Interim Financial Statements

for the period to 30th September, 2013

 

1 Basis of preparation

 

The interim financial statements have been prepared in accordance with the AIM rules and on the basis of all International Financial Reporting Standards ("IFRS") as adopted by the European Union that are expected to be applicable to the Company's statutory accounts for the year ended 31st March 2014. The interim financial statements are unaudited and were approved by the Directors on 9 December 2013. The information set out herein is abbreviated and does not constitute statutory accounts within the meaning of Section 434 of the Companies Act 2006.

 

The Company has not applied IAS 34, Interim Financial Reporting, which is not mandatory for UK Groups, in the preparation of these interim financial statements.

 

The Company is a limited liability company incorporated and domiciled in England & Wales and whose shares are quoted on AIM, a market operated by The London Stock Exchange. The financial information of Healthcare Investment Opportunities plc is presented in Pounds Sterling (£), which is also the functional currency of the Company.

 

 

2 Loss per share

 

Basic loss per share, from continuing operations, is calculated by dividing the earnings attributable to ordinary shareholders by the weighted average number of ordinary shares outstanding during the year.

 

The calculations of earnings per share are based on the following losses and numbers of shares.

 

6 months to

30 September 2013

 

Loss after taxation (62,631)

 

Weighted average number of shares 40,500,000

 

Basic earnings per share (0.15)p

 

At 30th September, 2013 the Company had 40,500,000 Ordinary Shares of 1p in issue.

 

The loss for the period and the weighted average number of ordinary shares for calculating the diluted earnings per share for the six months ended 30 September 2013 are identical to those used for the basic earnings per share.

 

3 Interim results

 These results were approved by the Board of Directors on 9 December 2013.

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
IR DDBDDCDGBGXC
Date   Source Headline
20th Feb 20197:00 amRNSSale of Strategic Investment in Jellagen
18th Feb 20197:00 amRNSPresenting at the Hardman Investor Forum
4th Feb 20193:55 pmRNSVisit from Member of Scottish Parliament
31st Jan 20197:00 amRNSChondroMimetic® Update
16th Jan 20194:52 pmRNSDirector/PDMR Shareholding
15th Jan 20197:00 amRNSNew Manufacturing Agreement
7th Jan 20193:45 pmRNSAward of £1.54 million Scottish Enterprise Grant
4th Dec 20187:00 amRNSHalf-year Report
7th Nov 20187:00 amRNSInvestor presentation
5th Nov 20187:00 amRNSRealignment of Bond Repayments
23rd Oct 20187:00 amRNSTrading Update and Notice of Results
18th Oct 20187:00 amRNSBiotech and Money's Inve$tival Showcase
26th Sep 20185:04 pmRNSHolding(s) in Company
25th Sep 20183:05 pmRNSDirector/PDMR Shareholding
19th Sep 20185:01 pmRNSDirector/PDMR Shareholding
3rd Sep 201812:20 pmRNSDirector/PDMR Shareholding
3rd Sep 20187:00 amRNSBoard Appointments
3rd Sep 20187:00 amRNSExecutive Share Options Alignment
24th Aug 201811:47 amRNSDirector/PDMR Shareholding
22nd Aug 201811:40 amRNSResult of AGM
22nd Aug 20187:00 amRNSAGM Statement
21st Aug 20187:00 amRNSAppointment of Distributors in China
25th Jul 20185:21 pmRNSPosting of Annual Report and Notice of AGM
10th Jul 20187:00 amRNSFinal Results
13th Jun 20187:00 amRNSNotice of Results
8th May 20187:00 amRNSExhibiting at 18th ESSKA conference
3rd May 20183:27 pmRNSDirector/PDMR Shareholding
11th Apr 20187:00 amRNSDirector/PDMR Shareholding
10th Apr 20187:00 amRNSAppointment of Chief Business Officer
6th Apr 20189:31 amRNSDirector/PDMR Shareholding
4th Apr 20187:00 amRNSTrading update
28th Mar 20187:00 amRNSProposed restructuring of New Zealand operations
1st Mar 20187:00 amRNSConference attendance
26th Feb 20187:15 amRNSHardman & Co: Nearing first proprietary product
22nd Feb 20181:00 pmRNSDirector/PDMR Shareholding
21st Feb 20187:00 amRNSPositive results of ChondroMimetic Clinical Study
15th Feb 20187:00 amRNSChina update
6th Feb 20187:00 amRNSInvestor presentation
20th Dec 201711:55 amRNSChondroMimetic® Update
19th Dec 20173:49 pmRNSHardman Research: Targeting long-term growth
18th Dec 20177:00 amRNSDirectorate Change
14th Dec 20177:00 amRNSAppointment of Chief Financial Officer
5th Dec 20177:00 amRNSHalf-year Report
27th Nov 20174:41 pmRNSSecond Price Monitoring Extn
27th Nov 20174:35 pmRNSPrice Monitoring Extension
26th Oct 20177:00 amRNSTrading update and notice of results
21st Sep 20171:28 pmRNSHardman Research: Engineering towards CE Mark
21st Sep 20177:00 amRNSStudy Update Patient Assessments Completed
18th Sep 20177:00 amRNSPresenting at the Hardman Investor Forum
12th Sep 20177:00 amRNSIssue of Equity

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.